P2.03-23 UHRF1 as a Potential Therapeutic Target for KRAS Mutated Non-Small Cell Lung Cancer
نویسندگان
چکیده
منابع مشابه
Realities of KRAS-mutated non-small cell lung cancer
Correspondence to Young Joo Min, M.D. Division of Oncology, Department of Hematology and Oncology, Ulsan University Hospital, 877 Bangeojinsunhwan-doro, Dong-gu, Ulsan 44033, Korea Tel: +82-52-250-8832 Fax: +82-52-251-8009 E-mail: [email protected] The most common histologic subtype of non-small cell lung cancer is adenocarcinoma. Adenocarcinoma has targetable gene alterations such as epidermal...
متن کاملSrc as a potential therapeutic target in non-small-cell lung cancer.
Lung cancer is the most common cause of cancer-related death, with non-small-cell lung cancer (NSCLC) accounting for 80%-85% of all cases. Although survival rates are reasonably good for patients diagnosed with very early disease, the majority of patients present with advanced disease. For these patients, palliation and improvements in quality of life are the primary goals of therapy. Although ...
متن کاملA RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer.
Of the numerous oncogenes implicated in human cancer, the most common and perhaps the most elusive to target pharmacologically is RAS. Since the discovery of RAS in the 1960s, numerous studies have elucidated the mechanism of activity, regulation, and intracellular trafficking of the RAS gene products, and of its regulatory pathways. These pathways yielded druggable targets, such as farnesyltra...
متن کاملHedgehog signaling: a potential therapeutic target for non-small cell lung cancer
HEDGEHOG SIGNALING: A POTENTIAL THERAPEUTIC TARGET FORNON-SMALL LUNG CANCERbyMA’IN MAITAHAugust 2011Advisor: Dr. Fazlul H. SarkarMajor: PathologyDegree: Doctor of Philosophy The American Cancer Society estimated that 222,520 Americans werediagnosed with lung cancer and 157,300 died of lung cancer in 2010 (Jemal etal. 2009, 225-249;Jemal et al. 2011, 69-90...
متن کاملHMGB1: A Potential Therapeutic Target for Non-Small Cell Lung Cancer
Recent studies have found HMGB1 as a potential and valuable bio-marker for NSCLC. Many targeted therapies have been developed with effective clinical proofs; however treatment responses are typically short-lived because of the frequent mutation of target genes. HMGB1 which has been targeted in several cancer therapies for its conservative feature would possess a potential clinical value for NSC...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2019
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2019.08.1470